The obvious rebuttal to these figures is that Trump’s investment figures are prospective—meaning they represent investments to come, not spending that has already happened. And that’s a fine point, given the announcements’ timing. Yet here, too, there are plenty of problems. For starters, the only actual evidence the White House has offered of a tariff-fueled “Trump Effect” on domestic investment
is a list of 132 “private and foreign investment” announcements it claims was “made possible by President Trump’s leadership.” But even that totals just
$9.6 trillion—a little more than
half of what Trump keeps claiming.
This hefty sum, moreover, is also wildly exaggerated. A
Bloomberg analysis of the White House’s “investment” list shows that about $2.6 trillion isn’t investment at all. Instead, it’s routine U.S. business expenses (e.g., worker training) or vague commitments to purchase U.S. goods. Some of those commitments, moreover, relate to military equipment that foreign governments (e.g., Saudi Arabia) already wanted to buy. Others, such as India’s
promises to stop buying Russian oil and start buying U.S. liquid natural gas, might never happen for practical and geopolitical reasons. Others still—as is the case of the EU’s purchase promises—simply
can’t happen because government officials in these places don’t have the authority to control private firms’ purchasing decisions.
The remaining $7 trillion on the White House list is split evenly between U.S. firms and overseas governments and companies, but there are big red flags here, too. “Most of the biggest investment plans,” Reynolds explains, came from large multinational corporations—Apple, Meta, Nvidia, Microsoft, Google, Micron, IBM, Eli Lilly, Pfizer, Merck, Johnson &Johnson, and AbbVie—that were already investing heavily in the United States and had already planned even more spending in the future, long before any tariff-induced “Trump Effect.”
As we
discussed last year, companies routinely repackage already-committed spending to curry favor with a new president, and various reports indicate that many of the “Trump Effect” investments
fit that bill. Here in North Carolina, for example, several major pharmaceutical investments have been
planned for years now, thanks in large part to the GLP‑1 drug frenzy.
Bloomberg’s analysis also finds that about 83 percent of the corporate investment pledges ($2.9 trillion of the total $3.5 trillion) listed by the White House are related to artificial intelligence and the huge data-center buildout. That spending is most definitely real and consequential, but it just as definitely wasn’t caused by Trump’s tariff threats.
www.whitehouse.gov
